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Introduction
Th   e ultimate aim of Alzheimer’s disease (AD) therapy is 
to stop or slow down the disease progression. Cholin-
esterase inhibitors have a modest clinical eﬀ  ect on the 
symptoms, however, and memantine – the currently 
available  N-methyl-d-aspartate receptor antagonist – 
does not prevent the deterioration of dementia [1,2]. 
Finding an eﬀ   ective method to treat   AD still poses a 
signiﬁ  cant clinical challenge.
Herbal medicine has long been used in China as 
therapy for dementia. Th  e Complete Work of Jingyue 
published in 1624 contains the earliest known description 
in the world of a herbal therapeutic strategy for dementia. 
In the past 10 years, however, herbal drugs have seldom 
been approved for use alone in treating dementia. 
Overall, systematic review has identiﬁ   ed a few single 
herbs and herbal formulations as possible eﬀ  ective 
medicine for AD (Table  1). According to the current 
evidence, some of these therapies show promising results 
in terms of their cognitive beneﬁ   ts. In the present 
commentary we discuss whether herbal therapy could be 
a novel pathway to treat AD, on the basis of the results 
from clinical trials, and the implications for potential 
therapy of AD pathophysiology.
Single herbs or extracts from herbs
Ginkgo biloba
Ginkgo biloba extract is among the most widely used 
complementary therapies. A Cochrane review included 
36 trials of gingko biloba, but most trials were small and 
of duration <3 months [3]. Nine trials were of 6 months 
duration and of adequate size, and were conducted to a 
reasonable standard. Of the four most recent trials to 
report results, three studies found no diﬀ  erence between 
Ginkgo biloba, at diﬀ  erent doses, and placebo [3], and 
one study found very large treatment eﬀ  ects in favor of 
Ginkgo biloba, but the trial sample size was very small 
[4]. Another recent trial reported negative results in 
reducing cognitive decline in older adults with normal 
cognition or with mild cognitive impairment [5]. Th  e 
current overall evidence that Ginkgo has a predictable 
and clinically signiﬁ  cant beneﬁ  t for people with dementia 
or cognitive impairment therefore seems inconsistent 
and unreliable.
Serrate clubmoss
Huperzine A extracted from the serrate clubmoss herb is a 
potent, reversible and selective inhibitor of acetyl-
cholinesterase. Considering the available evidence from six 
trials, Huperzine A seems to have some beneﬁ  cial eﬀ  ects 
on improvement of general cognitive function, global 
clinical status, behavioral disturbance and functional 
performance, with no obvious serious adverse events for 
patients with AD [6]. Only one study was of adequate 
quality and size, but the period during this study that 
found very large treatment eﬀ  ects was only 12 weeks [7]. 
Overall the current evidence supporting clinical use of 
Huperzine A is presently inconclusive or inadequate.
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Panaxi ginseng’s main active ingredient is panaxsaponin, 
which can enhance psychomotor and cognitive perfor-
mance, and can beneﬁ  t AD by improving brain cholin-
ergic function, reducing the level of Aβ and repairing 
damaged neuronal networks [8]. Th  e high-dose ginseng 
group showed statistically signiﬁ   cant improvement on 
the Alzheimer Disease Assessment Scale (ADAS) and 
Clinical Dementia Rating (but not on the Mini-Mental 
State Examination) at the end of the study, when com-
pared with the control group. Th  is study was poorly 
designed, with an insuﬃ   cient description of randomiza-
tion and without blinding. Furthermore, the sample size 
was small (n = 15 for each group), and there was also a 
confounding eﬀ   ect due to concurrently administered 
western medications [9]. Th  e evidence for ginseng as a 
treatment of AD is thus scarce and inconclusive. Further 
rigorous trials seem warranted [10].
Salvia offi   cinalis
Salvia oﬃ   cinalis has been used in herbal medicine for 
many centuries. After 4 months of treatment, salvia 
oﬃ   cinalis extract produced a signiﬁ  cantly better outcome 
on cognitive functions than placebo – as seen on the 
ADAS cognitive subscale and the Clinical Dementia 
Rating Sum of Boxes scale in patients with mild to 
moderate AD aged between 65 and 80 years [11]. Th  ere 
were no signiﬁ  cant diﬀ  erences between salvia oﬃ   cinalis 
and placebo in terms of the observed side eﬀ  ects.  In 
addition, salvia oﬃ     cinalis may reduce agitation in 
patients. More high-quality large-scale randomized 
controlled trials are needed, however, for further 
determination of the herb’s eﬃ   cacy [11].
Herbal formulations or mixtures of herbal 
ingredients
Herbal formulations or mixtures of herbal ingredients 
may have advantages with multiple target regulation 
compared with the single target antagonist in the view of 
traditional Chinese medicine, although there have been 
few clinical trials examining the eﬃ   cacy and safety of 
herbal formulations in AD patients.
Shenwu capsule, a mixture of six herbs that is thought 
to reduce amyloid cytotoxicity, increased the memory 
score from baseline (n = 83) – but without signiﬁ  cant 
diﬀ  erence from aniracetam (n = 83) – in a 12-week phase 
II trial for patients with mild cognitive impairment [12]. 
A phase III trial is now underway. Stilbene glycoside, an 
extract of Shenwu capsule, has been evaluated in a phase 
I trial for AD. Further results for both of these 
formulations will be available in the next few years.
GEPT, a combination of ﬁ  ve active components extracted 
from Chinese herbs, may be valuable for the treatment of 
AD – reducing the level of Aβ via the inhibition of γ-
secretase (presenilin-1) and the promotion of insulin-
degrading enzyme and neprilysin, which has been 
reported in the brain of APPV717I transgenic mice [13]. 
A 24-week preliminary study of GEPT showed a 
signiﬁ  cant improvement on cognitive function in patients 
with amnestic mild cognitive impairment, an early stage 
of AD (n = 101), consistently across diﬀ  erent cognitive 
scales; for example, an improvement in the ADAS 
cognitive subscale from baseline of –4.19 points (95% 
conﬁ  dence interval = –5.74 to –2.63), which declined at 
24 weeks of follow-up after the GEPT withdrawal. Th  is 
level of eﬃ   cacy was comparable with that of –4.23 points 
found in the subjects taking Donepezil (n = 100) 
Table 1. Diff  erent herbs and formulations eff  ective in the treatment of Alzheimer’s disease
Product Composition  Design  Outcome  measure  Source
Huperzine A  An extract from Lycopodium  A 12-week randomized, double-blind,   ADAS-cog, MMSE, CIBIC-plus, ADL of  Zhang and colleagues [7]
    placebo-controlled trial  patients with mild to moderate AD
Gingko Biloba  EGb 761  A 24-week randomized, placebo-  MMSE and CGI in patients with mild  Mazza and colleagues [4]
    controlled, double-blind study  to moderate AD
Panax ginseng  Ginsenosides  A 12-week open-label, randomized   ADAS and MMSE scores of AD  Lee and colleagues [17]
    double-blind, placebo-controlled   patients
   study
Salvia offi   cinalis  Leaf extract containing   A 4-month, parallel-group, placebo-  ADAS-cog and CDR in patients with  Akhondzadeh and
  monoterpene, fl  avonoids,   controlled trial  mild to moderate AD  colleagues [11]
 polyphenol
Ba Wei Di   Powder of Rehmannia with  An 8-week randomized, double-blind,   MMSE and Barthel Index scores in  Iwasaki and colleagues [15]
Hunag Wan  another seven plants mixed   placebo-controlled trial  patients with mild to severe dementia
 with  honey
Yi-Gan San   A mixture of seven diff  erent  A 4-week randomized, observer-  NPI and ADL in patients with mild to  Iwasaki and colleagues [16]
formula  rootstock and branches,   blind, controlled trial  severe dementia
  lyophilized dry extract
AD, Alzheimer disease; ADAS-cog, Alzheimer disease assessment scale-cognitive subscale; ADL, activities of daily living; CDR, Clinical Dementia Rating; CGI, Clinical 
Global Impression; CIBIC-plus, Clinician’s Interview-Based Impression of Change plus Caregiver Input; MMSE, mini-mental state examination; NPI, neuropsychiatric 
Inventory.
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trial.
Furthermore, the herbal preparations Ba Wei Di Huang 
Wan and Yi-Gan San are individually reported to signiﬁ  -
cantly improve cognition or behavior and function on the 
Mini-Mental State Examination, the Neuro  psychi  atric 
Inventory and the Barthel Index in the patients with AD 
[15,16].
Conclusion
Single herbs or formulations may be able to complement 
approved drugs for AD. No serious adverse events have 
been reported. Th   e current evidence to support their use 
alone, however, is inconclusive or inadequate. Th  is un-
certainty is mainly caused by methodological limitations 
such as poor study design, relatively small sample sizes 
without a power calculation, inappropriate outcome 
measures and primary and secondary end-point selec-
tion, and invalid statistical analysis. In addition, the 
herbs’ potential value for prevention and treatment of 
AD only results from symptomatic changes and short 
treatment periods (<6 months). Several studies currently 
underway or in early-stage development in China to 
evaluate herb mixtures will hopefully show promising 
results in the near future.
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